美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Arin Tactical Tail Risk ETF

90.92

+0.32510.36%

成交量：486.00

成交额：4.42万

市值：8,992.82万

市盈率：- -

高：91.08

开：90.93

低：90.92

收：90.59

52周最高：91.56

52周最低：45.10

股本：98.91万

流通股本：98.91万

量比：0.78

换手率：0.05%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

从“跑不动” 到 “有药治”：“淀粉人”治疗即将迎来重大突破

万诺维®在华获批用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病（ATTRv-PN）患者

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ATTR/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":90.915,"timestamp":1774296000000,"preClose":90.5899,"halted":0,"volume":486,"delay":0,"changeRate":0.0035887002855727423,"floatShares":989146,"shares":989146,"eps":0,"marketStatus":"盘后交易","change":0.3251,"latestTime":"03-23 16:51:18 EDT","open":90.93,"high":91.08,"low":90.915,"amount":44226.76,"amplitude":0.001821,"askPrice":136.44,"askSize":200,"bidPrice":81.85,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774310400000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":90.5899,"sharesOutstanding":989146,"nav":91,"aum":90012286,"bidAskSpread":0,"volumeRatio":0.782105},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":989146,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.782105,"shares":989146,"dividePrice":0,"high":91.08,"amplitude":0.001821,"preClose":90.5899,"low":90.915,"week52Low":45.1,"pbRate":"--","week52High":91.56,"institutionHeld":0,"latestPrice":90.915,"committee":-0.333333,"eps":0,"divideRate":0,"volume":486,"delay":0,"ttmEps":0,"open":90.93,"prevYearClose":90.4492,"prevWeekClose":90.5899,"prevMonthClose":91.5007,"prevQuarterClose":90.4492,"fiveDayClose":90.9741,"twentyDayClose":91.2697,"sixtyDayClose":90.5445},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2594239863","title":"从“跑不动” 到 “有药治”：“淀粉人”治疗即将迎来重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2594239863","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594239863?lang=zh_cn&edition=fundamental","pubTime":"2025-12-25 18:09","pubTimestamp":1766657357,"startTime":"0","endTime":"0","summary":"2016年的一天，老王（化名）的生活被一场突如其来的变化打破——他忽然发现自己再也跑不动了，脚腕像灌了铅般沉重。这份不适并未止步，反而一步步侵袭全身：从最初的四肢无力，逐渐发展为呼吸困难、肌肉萎缩。为了查明病因，他辗转七家医院、问诊二十余位医生，历经整整五年的漫长求索，才终于被明确诊断为转甲状腺素蛋白淀粉样变性（ATTR）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601978880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ATTR"],"gpt_icon":0},{"id":"2594236078","title":"万诺维®在华获批用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病（ATTRv-PN）患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2594236078","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594236078?lang=zh_cn&edition=fundamental","pubTime":"2025-12-25 17:10","pubTimestamp":1766653800,"startTime":"0","endTime":"0","summary":"依普隆特生钠是中国首个且目前唯一获批用于ATTRv-PN治疗的基因沉默剂。\" 依普隆特生钠已在美国和欧盟获批用于治疗ATTRv-PN，并正在全球更多国家和地区推进审批进程。依普隆特生钠目前正在开展CARDIO-TTRansform III期临床研究，旨在评估其用于治疗成人转甲状腺素蛋白心脏淀粉样变心肌病的疗效。作为RNA靶向治疗药物，它可在肝脏源头减少TTR蛋白的产生，因而具有潜力用于治疗各类型的转甲状腺素蛋白介导的淀粉样变性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4853711_ZH53711_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["HF","LU0320765992.SGD","LU2462157665.USD","BK4568","AZN","LU0889565916.HKD","BK4007","BK4082","CV","LU1829250122.USD","LU2236285917.USD","LU0109394709.USD","ATTR","LU2417539215.USD","LU2456880835.USD","BK4588","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}